Lexchin相关文献与解析，生知库 | 链接生命科学的每一步

Information About Canadian Patient Groups' Conflicts of Interest and Industry Funding-Incomplete, Inconsistent, and Unreliable: A Cross-Sectional Study

加拿大患者团体利益冲突和行业资助信息——不完整、不一致且不可靠：一项横断面研究

期刊:

影响因子:

doi:10.1177/27551938251325801

Lexchin, Joel

发表日期：2025

文献求助收藏

Are Therapeutically Important Drugs No Longer Available in Canada?

加拿大是否已不再提供具有重要治疗价值的药物？

期刊:

影响因子:

doi:10.12927/hcpol.2025.27666

Lexchin, Joel

发表日期：2025

文献求助收藏

Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study

加拿大卫生部有条件批准的肿瘤产品的治疗价值：一项横断面研究

期刊:JRSM Open

影响因子:

doi:10.1177/20542704251325314

Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap"

利润至上，健康其次：制药行业和全球南方国家就《付出更多，收获更多！新冠疫苗的交付以及制药行业在扩大疫苗获取差距中的作用》一文发表评论

期刊:International Journal of Health Policy and Management

影响因子:5.1

doi:10.34172/ijhpm.2024.8471

Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials

加拿大临床试验中心开展的IV期药物试验：企业资助试验与非企业资助试验的比较

期刊:International Journal of Health Policy and Management

影响因子:5.1

doi:10.34172/ijhpm.2024.8239

Lexchin, Joel; Dong, Blue Miaoran; Ramanathan, Aravind; Gagnon, Marc-André

发表日期：2024

文献求助收藏

The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program

《全面与进步跨太平洋伙伴关系协定》对泰国丙型肝炎治疗计划的潜在影响

期刊:Globalization and Health

影响因子:4.5

doi:10.1186/s12992-024-01053-9

Tenni, Brigitte; Lexchin, Joel; Akaleephan, Chutima; Kittitrakul, Chalermsak; Gleeson, Deborah

肝炎

发表日期：2024

文献求助收藏

Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study

加拿大卫生部批准的孤儿药的治疗价值：一项横断面研究

期刊:Journal of General Internal Medicine

影响因子:4.2

doi:10.1007/s11606-024-08651-8

Lexchin, Joel

发表日期：2024

文献求助收藏

Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study

Prescrire 对加拿大“不可接受”药物的评估：一项队列研究

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0308118

Lexchin, Joel

发表日期：2024

文献求助收藏

Orphan Drug Approval in Canada, 1999-2022: A Cross-sectional Study

1999-2022年加拿大孤儿药审批情况：一项横断面研究

Weight normativity in action: Semaglutide and obesity

体重规范化实践：索玛鲁肽与肥胖

Information About Canadian Patient Groups' Conflicts of Interest and Industry Funding-Incomplete, Inconsistent, and Unreliable: A Cross-Sectional Study

加拿大患者团体利益冲突和行业资助信息——不完整、不一致且不可靠：一项横断面研究

Are Therapeutically Important Drugs No Longer Available in Canada?

加拿大是否已不再提供具有重要治疗价值的药物？

Therapeutic value of oncology products with a conditional approval from Health Canada: a cross-sectional study

加拿大卫生部有条件批准的肿瘤产品的治疗价值：一项横断面研究

Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap"

利润至上，健康其次：制药行业和全球南方国家就《付出更多，收获更多！新冠疫苗的交付以及制药行业在扩大疫苗获取差距中的作用》一文发表评论

Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials

加拿大临床试验中心开展的IV期药物试验：企业资助试验与非企业资助试验的比较

The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program

《全面与进步跨太平洋伙伴关系协定》对泰国丙型肝炎治疗计划的潜在影响

Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study

加拿大卫生部批准的孤儿药的治疗价值：一项横断面研究

Canadian status of "not acceptable" drugs as evaluated by Prescrire: A cohort study

Prescrire 对加拿大“不可接受”药物的评估：一项队列研究